Bisphosphonates in complex regional pain syndrome type I: How do they work?

Clinical and Experimental Rheumatology

Volumn 32, Issue 4, 2014, Pages 451-454

  Varenna, Massimo ^a   Adami, Silvano ^b   Sinigaglia, Luigi ^a  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Bisphosphonates; Complex regional pain syndrome; Treatment

Indexed keywords

ACID SENSING ION CHANNEL; BISPHOSPHONIC ACID DERIVATIVE; ENDOTHELIN 1; GERANYLTRANSFERASE; LACTIC ACID; NERVE GROWTH FACTOR; NEUROPEPTIDE; RAB PROTEIN; RAC PROTEIN; RAS PROTEIN; RHO FACTOR; VANILLOID RECEPTOR 1;

ACIDOSIS; BINDING SITE; CELL ACTIVATION; CELL PROLIFERATION; CELL VIABILITY; COMPLEX REGIONAL PAIN SYNDROME TYPE I; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG UPTAKE; EDITORIAL; ENZYME INHIBITION; HUMAN; INCIDENCE; MACROPHAGE; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ANALGESICS; DIPHOSPHONATES; HUMANS; PAIN MEASUREMENT; PATIENT SELECTION; REFLEX SYMPATHETIC DYSTROPHY; TREATMENT OUTCOME;

EID: 84904892269     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Editorial

References (59)

1. VARENNA M, ADAMI S, ROSSINI M et al.: Treatment of complex regional pain syndrome with neridronate: a randomized, double- blind, placebo-controlled study. Rheumatology (Oxford) 2013; 52: 534-42.
2. ADAMI S, FOSSALUZZA V, GATTI D, FRACASSI E, BRAGA V: Bisphosphonate therapy of reflex sympathetic dystrophy syndrome. Ann Rheum Dis 1997; 56: 201-4.
3. VARENNA M, ZUCCHI F, GHIRINGHELLI D et al.: Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study. J Rheumatol 2000; 27: 1477-83.
4. ROBINSON JN, SANDOM J, CHAPMAN PT: Efficacy of pamidronate in complex regional pain syndrome type I. Pain Med 2004; 5: 276-80.
5. MANICOURT DH, BRASSEUR JP, BOUTSEN Y, DEPRESEUX G, DEVOGELAER JP: Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity. Arthritis Rheum 2004; 50: 3690-7.
6. RENIER JC, BASLE M, ARLET J et al.: L'os et le métabolisme phosphocalcique dans l'algo-dystrophie. Rev Rhum Mal Osteoartic 1983; 50: 23-31.
7. BASLE MF, REBEL A, RENIER JC: Bone tissue in reflex sympathetic dystrophy syndrome - Sudeck's atrophy: structural and ultrastructural studies. Metab Bone Dis Relat Res 1983; 4: 305-11.
8. ARLET J, FICAT CCJ: Vascular explorations and pathology of reflex sympathetic dystrophy. Baillere's Clin Orthop 1996; 2: 273-90.
9. LEE GW, WEEKS PM: The role of bone scintigraphy in diagnosing Reflex Sympathetic Dystrophy. J Hand Surg 1995; 20A: 458-63.
10. LEITHA T, KORPAN M, STAUDENHERZ A, WUNDERBALDINGER P, FIALKA V: Five phase bone scintigraphy supports the pathophysiological concept of a subclinical inflammatory process in reflex sympathetic dystrophy. Q J Nucl Med 1996; 40: 188-93.
11. HOFMANN S, FIALKA V, KRAMER J et al.: Bone marrow oedema syndrome of the hip and its relationship to avascular necrosis and reflex sympathetic dystrophy. Baillere's Clin Orthop 1996; 2: 291-313.
12. CHAPURLAT RD, DUBOEUF FP, LIENS D, MEUNIER PJ: Dual energy X-ray absorptiometry in patients with lower limb reflex sympathetic dystrophy syndrome. J Rheumatol 1996; 9: 1557-9.
13. ARRIAGADA M, ARINOVICHE R: X-ray bone densitometry in the diagnosis and follow-up of reflex sympathetic dystrophy syndrome. J Rheumatol 1994; 21: 498-500.
14. BICKERSTAFF DR, CHARLESWORTH D, KANIS JA: Changes in cortical and trabecular bone in algodystrophy. Br J Rheumatol 1993; 32: 46-51.
15. BIRKLEIN F, WEBER M, NEUNDÖRFER B: Increased skin lactate in complex regional pain syndrome: evidence for tissue hypoxia? Neurology 2000; 55: 1213-5.
16. EVANS JR, ROBERTSON WG, MORGAN DB, FLEISCH H: Effect of pyrophosphate and diphosphonates on the dissolution of hydroxyapatites using a flow system. Calcif Tissue Int 1980; 31: 153-9.
17. FAST DK, FELIX R, DOWSE C, NEUMAN WF, FLEISCH H: The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem J 1978; 172: 97-107.
18. MacMAHON SB, JONES NJ: Plasticity of pain signaling: role of neurotrophic factors exemplified by acid-induced pain. J Neurobiol 2004; 61: 72-87.
19. MACH DB, ROGERS SD, SABINO MC et al.: Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 2002; 113: 155-66.
20. WALDMANN R, CHAMPIGNY G, LINGUEGLIA E, de WEILLE JR, HEURTEAUX C, LAZDUNSKI M: H(+)-gated cation channels. Ann NY Acad Sci 1999; 868: 67-76.
21. NAGAE M, HIRAGA T, YONEDA T: Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization. J Bone Miner Metab 2007; 25: 99-104.
22. TAN EC, OYEN WJ, GORIS RJ: Leukocytes in complex regional pain syndrome type I. Inflammation 2005; 29: 182-6.
23. CECCHINI MG, FELIX R, FLEISCH H, COOPER PH: Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res 1987; 2: 135-42.
24. STEVENSON PH, STEVENSON JR: Cytotoxic and migration inhibitory effects of bisphosphonates on macrophages. Calcif Tissue Int 1986; 38: 227-33.
25. ROGERS MJ, CHILTON KM, COXON FP et al.: Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide- independent mechanism. J Bone Miner Res 1996; 11: 1482-91.
26. CECCHINI MG, FLEISCH H: Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 1990; 5: 1019-27.
27. RITZ BW, ALEXANDER JM, NOGUSA S et al.: Elevated blood levels of inflammatory monocytes (CD14+CD16+) in patients with complex regional pain syndrome. Clin Exp Immunol 2011; 164: 108-17.
28. MARCHAND F, PERRETTI M, McMAHON SB: Role of the immune system in chronic pain. Nat Rev Neurosci 2005; 7: 521-32.
29. ALEXANDER GM, van RIJN MA, van HILTEN JJ, PERREAULT MJ, SCHWARTZMAN RJ: Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain 2005; 116: 213-9.
30. MAIHÖFNER C, HANDWERKER HO, NEUNDÖRFER B, BIRKLEIN F: Mechanical hyperalgesia in complex regional pain syndrome: a role for TNF-alpha? Neurology 2005; 65: 311-3.
31. UÇEYLER N, EBERLE T, ROLKE R, BIRKLEIN F, SOMMER C: Differential expression patterns of cytokines in complex regional pain syndrome. Pain 2007; 132: 195-205.
32. SANSONI P, PASSERI G, FAGNONI F et al.: Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 1995; 10: 1719-25.
33. MAKSYMOWYCH WP: Bisphosphonates. Anti- inflammatory properties. Curr Med Chem Anti Inflamm Anti Allergy Agents 2002; 1: 15-28.
34. BENNETT DL, KOLTZENBURG M, PRIESTLEY JV, SHELTON DL, McMAHON SB: Endogenous nerve growth factor regulates the sensitivity of nociceptors in the adult rat. Eur J Neurosci 1998; 10: 1282-91.
35. DONNERER J, SCHULIGOI R, STEIN C: Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience 1992; 49: 693-8.
36. SABSOVICH I, WEI T, GUO TZ et al.: Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type. Pain 2008; 138: 47-60.
37. EHRHARD PB, GANTER U, STALDER A, BAUER J, OTTEN U: Expression of functional trk protooncogene in human monocytes. Proc Natl Acad Sci USA 1993; 90: 5423-7.
38. JI RR, SAMAD TA, JIN SX, SCHMOLL R, WOOLF CJ: p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 2002; 36: 57-68.
39. LI WW, GUO TZ, LI XQ, KINGERY WS, CLARK JD: Fracture induces keratinocyte activation, proliferation, and expression of pro-nociceptive inflammatory mediators. Pain 2000; 151: 843-52.
40. MARINUS J, MOSELEY GL, BIRKLEIN F et al.: Clinical features and pathophysiology of complex regional pain syndrome. Lancet Neurol 2011; 10: 637-48.
41. BURBACH GJ, KIM KH, ZIVONY AS et al.: The neurosensory tachykinins substance P and neurokinin A directly induce keratinocyte nerve growth factor. J Invest Dermatol 2001; 117: 1075-82.
42. McKENZIE RC, SAUDER DN: The role of kera-tinocyte cytokines in inflammation and immunity. J Invest Dermatol 1990; 95: 105S-7S.
43. BIRKLEIN F, SCHMELZ M: Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). Neurosci Lett 2008; 437: 199-202.
44. RESZKA AA, HALASY-NAGY J, RODAN GA: Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation. Mol Pharmacol 2001; 59: 193-202.
45. LUCKMAN SP, HUGHES DE, COXON FP, GRAHAM R, RUSSELL G, ROGERS MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-9.
46. HOLLMANN MW, STRUMPER D, HERROEDER S, DURIEUX ME: Receptors, G proteins, and their interactions. Anesthesiology 2005; 103: 1066-78.
47. MALIN SA, MOLLIVER DC: Gi- and Gq-coupled ADP (P2Y) receptors act in opposition to modulate nociceptive signaling and inflammatory pain behavior. Mol Pain 2010; 6: 21.
48. FLEISCH H: Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.
49. PASPALIARIS V, LEAVER DD: Clodronate inhibits contraction and prevents the action of L-type calcium channel antagonists in vascular smooth muscle. J Bone Miner Res 1991; 6: 835-41.
50. MUIZELAAR JP, KLEYER M, HERTOGS IA, DeLANGE DC: Complex regional pain syndrome (reflex sympathetic dystrophy and causalgia): management with the calcium channel blocker nifedipine and/or the alpha-sympathetic blocker phenoxybenzamine in 59 patients. Clin Neurol Neurosurg 1997; 99: 26-30.
51. GROENEWEG G, HUYGEN FJ, NIEHOF SP et al.: Effect of tadalafil on blood flow, pain, and function in chronic cold complex regional pain syndrome: a randomized controlled trial. BMC Musculoskelet Disord 2008; 9: 143.
52. ROSSIER JR, COX JA, NIESOR EJ, BENTZEN CL: A new class of calcium entry blockers defined by 1,3-diphosphonates. Interactions of SR-7037 (belfosdil) with receptors for calcium channel ligands. J Biol Chem 1989; 26: 16598-607.
53. PLOTKIN LI, WEINSTEIN RS, PARFITT AM, ROBERSON PK, MANOLAGAS SC, BELLIDO T: Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 1999; 104: 1363-74.
54. NEVES M, GANO L, PEREIRA N et al.: Synthesis, characterization and biodistribution of bisphosphonates Sm-153 complexes: correlation with molecular modeling interaction studies. Nucl Med Biol 2002; 29: 329-38
55. WASNER G: Vasomotor disturbances in complex regional pain syndrome. A review. Pain Med 2010; 11: 1267-73.
56. CODERRE TJ, BENNETT GJ: A hypothesis for the cause of complex regional pain syndrome- type I (reflex sympathetic dystrophy): pain due to deep-tissue microvascular pathology. Pain Med 2010; 11: 1224-38.
57. GUO TZ, OFFLEY SC, BOYD EA, JACOBS CR, KINGERY WS: Substance P signaling contributes to the vascular and nociceptive abnormalities observed in a tibial fracture rat model of complex regional pain syndrome type I. Pain 2004; 108: 95-107.
58. de MOS M, de BRUIJN AGJ, HUYGEN FJPM, DIELEMAN JP, STRICKER BH, STURKENBOOM MC: The incidence of complex regional pain syndrome: A population-based study. Pain 2007; 129: 12-20.
59. McKIERNAN FE: Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult. Osteoporos Int 2005; 16: 1698-702.